Envestnet Asset Management
GALT icon

Envestnet Asset Management’s Galectin Therapeutics GALT Stock Holding History

Envestnet Asset Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-5
Closed – – 2429
2013
Q2 		$0 Buy
+5
New +$20 ﹤0.01% 2339

Other funds holding GALT

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $871M AUM 27.72% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Envestnet Asset Management's GALT Position: Q3 2013 in Review

Envestnet Asset Management sold out of Galectin Therapeutics (GALT) in Q3 2013, closing a stake of 5 shares.

Envestnet Asset Management first reported a position in GALT in Q2 2013 and held it in 1 quarter. The position peaked at $0 in Q2 2013. 26 funds tracked by Wall St. Rank hold GALT as of Q3 2013.

  • Envestnet Asset Management reported no remaining Galectin Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Envestnet Asset Management sold 5 Galectin Therapeutics shares in Q3 2013.
  • Envestnet Asset Management first reported a position in Galectin Therapeutics in Q2 2013 and held it in 1 quarter.
  • Envestnet Asset Management's Galectin Therapeutics position peaked at $0 in Q2 2013.
  • 26 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2013.

Based on Envestnet Asset Management's 13F filing for Q3 2013, filed 12 Nov 2013.